You Can Teach an Old Drug New Tricks

Comment

M Scott Perry. Epilepsy Curr. 2020.

. 2020 May 12;20(4):193-195.

doi: 10.1177/1535759720923035. eCollection 2020 Jul-Aug.

No abstract available

Comment on

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Nabbout R, et al. JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. JAMA Neurol. 2020. PMID: 31790543 Free PMC article. Clinical Trial.

1. Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomized, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–2254. doi:10.1016/s0140-6736(19)32500-0 - PubMed
1. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(5):2011–2020. - PubMed
1. Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome—a randomized clinical trial. JAMA Neurol. 2020;77(5):613–621. - PMC - PubMed
1. Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. Cochrane Database Syst Rev. 2017;5(1):CD010483. - PMC - PubMed
1. Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neuro. 2020;77(3):300–308. doi:10.1001/jamaneurol.2019.4113 - PMC - PubMed